利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

152 条记录 (耗时 0.101 秒)

    DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF
    81.
    发明申请
    DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF 有权
    人乳清蛋白（HMOs）或其前体的多样性

    公开(公告)号：US20140212930A1

    公开(公告)日：2014-07-31

    申请号：US14117332

    申请日：2012-05-14

    申请人： Gyula Dekany ,  Elise Champion ,  Andreas Schroven ,  Markus Hederos

    发明人： Gyula Dekany ,  Elise Champion ,  Andreas Schroven ,  Markus Hederos

    IPC分类号： C12P19/14 ,  C12P19/12 ,  C12P19/04

    CPC分类号： C12P19/14 ,  C07H1/00 ,  C07H5/04 ,  C07H13/04 ,  C12P19/04 ,  C12P19/12

    摘要： A method of diversification of human milk oligosaccharides (HMOs) or precursors thereof, compounds obtainable by the method, and uses and compositions involving such compounds. The method comprises a) providing at least one compound or a mixture of the compounds selected from the group consisting of: optionally sialylated and/or fucosylated lactose derivatives of general formula 2 and salts thereof; b) adding at least one enzyme comprising a transglycosidase activity to the at least one compound or a mixture of compounds provided according to step a); and c) incubating the mixture obtained according to step b).

    摘要翻译： 人乳寡糖（HMO）或其前体多样化的方法，可通过该方法获得的化合物以及涉及这些化合物的用途和组合物。 该方法包括：a）提供至少一种化合物或选自下组的化合物或混合物：选自唾液酸化的和/或通式2的岩藻糖化的乳糖衍生物及其盐; b）向所述至少一种化合物或根据步骤a）提供的化合物的混合物中加入至少一种包含转糖苷酶活性的酶; 和c）孵育根据步骤b）获得的混合物。

    N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
    83.
    发明申请
    N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE 有权
    N-取代的曼诺糖胺衍生物，其制备方法及其使用

    公开(公告)号：US20140046051A1

    公开(公告)日：2014-02-13

    申请号：US14111131

    申请日：2012-04-11

    申请人： Ioannis Vrasidas ,  Gyula Dekany ,  Ågnes Jánosi ,  Markus Hederos ,  Christoph Röhrig

    发明人： Ioannis Vrasidas ,  Gyula Dekany ,  Ågnes Jánosi ,  Markus Hederos ,  Christoph Röhrig

    IPC分类号： C07H5/06 ,  C07H13/04

    CPC分类号： C07H5/06 ,  C07H13/04 ,  C07H15/18

    摘要： A compound of the formula (1) wherein R1 is a group removable by hydrogenolysis, and wherein R2 is OH or R2 is —NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The compound can be used then to make free D-mannosamine or its salts, D-mannosamine building blocks and mannosamine containing oligo- or polysaccharides, N-acetyl-D-mannosamine and its hydrates and solvates, neuraminic acid derivatives, and viral neuraminidase inhibitors.

    摘要翻译： 式（1）的化合物，其中R 1是通过氢解除去的基团，并且其中R 2是OH或R 2是-NHR 3，其中R 3是通过氢解除去的基团。 该化合物可以通过海恩斯重排由果糖制成。 然后可以使用该化合物制备游离的D-甘露糖胺或其盐，D-甘露糖胺结构单元和含有甘露糖胺的寡糖或多糖，N-乙酰基-D-甘露糖胺及其水合物和溶剂合物，神经氨酸衍生物和病毒神经氨酸酶抑制剂 。

    CARBOHYDRATE DERIVATIVES
    85.
    发明申请
    CARBOHYDRATE DERIVATIVES 有权
    碳氢化合物衍生物

    公开(公告)号：US20110060139A1

    公开(公告)日：2011-03-10

    申请号：US12741973

    申请日：2008-11-03

    申请人： Gyula Dekany ,  István Bajza ,  Marie Bøjstrup ,  Karoly Agoston ,  Lars Kröger ,  Figueroa Peréz ,  Christoph Röhrig ,  Paulo Vital ,  Erzsébet Czinege

    发明人： Gyula Dekany ,  István Bajza ,  Marie Bøjstrup ,  Karoly Agoston ,  Lars Kröger ,  Figueroa Peréz ,  Christoph Röhrig ,  Paulo Vital ,  Erzsébet Czinege

    IPC分类号： C07H5/06 ,  C08B37/00

    CPC分类号： C07H15/12 ,  C07H5/06 ,  C07H15/203

    摘要： A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.

    摘要翻译： 描述了其通式1及其衍生物所示的其游离碱，盐或金属络合物形式的1,2-二脱氧-1,2-二氨基寡糖或多糖。 R 1，R 2和R 3各自独立地选自H和碳水化合物部分，条件是基团R 1，R 2或R 3中的至少一个是碳水化合物部分; R 4选自：H，任选取代的C 1-20 - 烷基，任选取代的杂烷基，任选取代的C 2-20 - 烯基，任选取代的C 2-20 - 炔基，任选取代的C 3-10 - 环烷基，任选取代的杂环基 ，任选取代的芳基和任选取代的杂芳基。

    HMO PRODUCTION
    87.
    发明公开
    HMO PRODUCTION 审中-公开

    公开(公告)号：US20230227876A1

    公开(公告)日：2023-07-20

    申请号：US17759273

    申请日：2021-01-22

    申请人： GLYCOM A/S

    发明人： Margit PEDERSEN ,  Katrine Bych KAMPMANN

    IPC分类号： C12P19/00 ,  C07K14/24

    CPC分类号： C12P19/00 ,  C07K14/24

    摘要： The present invention relates to the field of recombinant production of biological molecules in host cells. More particularly it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS).

    Synthetic composition for microbiota modulation
    88.
    发明授权
    Synthetic composition for microbiota modulation 有权

    公开(公告)号：US11696921B2

    公开(公告)日：2023-07-11

    申请号：US17001118

    申请日：2020-08-24

    申请人： GLYCOM A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell

    IPC分类号： A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

    CPC分类号： A61K31/702 ,  A61K9/0053 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10

    摘要： A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro¬intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.